The following recommendations are provided to colleges and universities to facilitate the implementation of a comprehensive institutional prematriculation immunization policy. Vaccine-preventable diseases continue to occur on American campuses. In response to changing epidemiology and the introduction of new vaccines, the ACHA Vaccine Preventable Diseases Committee monitors age-appropriate public health recommendations and updates this document accordingly.

The committee recognizes that many colleges and universities are mandated by state law to require certain vaccinations for matriculating students. States and educational institutions may require fewer or more vaccines, while some may only recommend certain vaccinations. This document is intended as a guideline that is consistent with the Advisory Committee on Immunization Practices (ACIP) recommendations. Links to complete information regarding ACIP provisional and final comprehensive recommendations, including schedules, indications, precautions, and contraindications, are available at the CDC National Immunization Program website: http://www.cdc.gov/nip/publications/ACIP-list.htm.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Vaccination Schedule</th>
<th>Major Indications</th>
<th>Contraindications and Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measles, Mumps, Rubella</td>
<td>Two doses of MMR at least 28 days apart after 12 months of age.</td>
<td>All college students born after 1956 without lab evidence of disease or physician diagnosed disease.</td>
<td>Pregnancy, history of hypersensitivity or anaphylaxis to any of the components in the vaccine. Receipt of blood products and moderate or severe acute infections. Guidelines exist for vaccination of persons with altered immunocompetence.</td>
</tr>
<tr>
<td>(MMR)</td>
<td></td>
<td>All health sciences students without other evidence of immunity should receive two doses of MMR. Those born before 1957 without other evidence of immunity should receive one dose if not in an outbreak setting and two doses if in an outbreak.</td>
<td></td>
</tr>
<tr>
<td>Polio</td>
<td>Two doses of varicella-containing vaccine at least 12 weeks apart if vaccinated between 1 and 12 years of age and at least 4 weeks apart if vaccinated at age 13 years or older.</td>
<td>All college students without other evidence of immunity (e.g., born in the U.S. before 1980, a history of disease, two prior doses of varicella vaccine, or a positive antibody). All health sciences students without a history of disease, with one prior dose of vaccine, or with a negative antibody titer should receive a total of two doses of vaccine.</td>
<td>Pregnancy, history of hypersensitivity or anaphylaxis to any of the components in the vaccine, and severe illness. Guidelines exist for vaccination of persons with altered immunocompetence.</td>
</tr>
<tr>
<td>- Inactivated (IPV)</td>
<td>Primary series in childhood with IPV alone, OPV alone, or IPV/OPV sequentially; IPV booster only if needed for travel after age 18 years.</td>
<td>IPV for certain international travelers to areas or countries where polio is epidemic or endemic.</td>
<td>History of hypersensitivity to any of the components of the vaccine.</td>
</tr>
<tr>
<td>- Oral poliovirus (OPV - no longer available in U.S.)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccine</td>
<td>Vaccination Schedule</td>
<td>Major Indications</td>
<td>Contraindications and Precautions</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------</td>
<td>-------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>Tetanus, Diphtheria, Pertussis</td>
<td></td>
<td></td>
<td>History of hypersensitivity or serious adverse reaction to any of the components in the vaccine.</td>
</tr>
</tbody>
</table>

- **DT**: pediatric (< age 7 years) preparation of diphtheria and tetanus toxoids.
- **DTP**: pediatric (< age 7 years) preparation of diphtheria, tetanus toxoids, and acellular pertussis.
- **DTaP**: pediatric (< age 7 years) preparation of diphtheria, tetanus toxoids, and acellular pertussis.
- **DTP (also known as DTwP)**: pediatric (< age 7 years) preparation of diphtheria, tetanus toxoids, and whole cell pertussis (no longer available in the U.S.).
- **Td**: 7 years and older preparation of tetanus toxoid and reduced diphtheria toxoid.
- **Tdap**: adolescent and older preparation of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis.

**Tetanus prophylaxis in wound management**: For both age groups above, patients who require a tetanus toxoid-containing vaccine as part of wound management should receive Tdap instead of Td if they have not previously received Tdap. If Tdap is not available or was administered previously, Td should be administered.

**Pertussis prophylaxis**: For both age groups above, intervals shorter than 10 years since the last Td may be used to protect against pertussis. Particularly in settings with increased risk from pertussis or its complications or for those who have or who anticipate having close contact with an infant < 12 months of age (parents, childcare providers, healthcare providers), a single dose of Tdap should be administered. The benefits of using a single dose of Tdap at a shorter interval to protect against pertussis generally outweighs the risk of local and systemic reactions after vaccination. The safety of intervals as short as 2 years between Td and Tdap are supported by studies from Canada.

**Routine booster dose intervals**: Adults should receive decennial Td boosters, beginning 10 years after receiving Tdap, until guidance on subsequent Tdap booster doses is available.

One dose of Tdap replacing one decennial Td booster for all college students.

Any student in the setting of pertussis outbreaks, close contact with infants less than 12 months of age, or wound management, as appropriate.

Health sciences students with patient contact should receive a single dose of Tdap at an interval as short as two years from the last Td. Health sciences students with no patient contact should receive a single dose of Tdap according to the routine recommendation and interval guidance for use of Tdap in adults.

One dose of Tdap replacing one decennial Td booster for all college students.
<table>
<thead>
<tr>
<th>VACCINE</th>
<th>VACCINATION SCHEDULE</th>
<th>MAJOR INDICATIONS</th>
<th>CONTRAINDICATIONS AND PRECAUTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Quadrivalent Human Papillomavirus Vaccine (HPV)</strong></td>
<td>Females 11 or 12 years old. All females age 13-26 years old who have not received the vaccine (three doses at 0, 2, and 6 months).</td>
<td>All female college students 11 to 26 years old. No HPV or pap test screening is required prior to administering vaccine; however, routine cervical cancer screening should continue according to prior recommendations.</td>
<td>Pregnancy, history of hypersensitivity to yeast or to any vaccine component; moderate or severe acute illnesses (defer vaccine until improved); may be given to immunocompromised females, but vaccine responsiveness and efficacy may be reduced.</td>
</tr>
<tr>
<td><strong>Hepatitis A Vaccine</strong></td>
<td>Given as a series of 2 doses (given at 0, 6-12 mo.) for age 12 months or greater. **</td>
<td>Recommended for routine use in all adolescents through the age of 18 and in particular for adolescent and adult high-risk groups (i.e., persons traveling to countries where hepatitis A is moderately or highly endemic, men who have sex with men, users of injectable and noninjectable drugs, persons who have clotting-factor disorders, persons working with nonhuman primates, and persons with chronic liver disease).</td>
<td>History of hypersensitivity to any of the components of the vaccine.</td>
</tr>
<tr>
<td><strong>Hepatitis B Vaccine</strong></td>
<td>Given as a series of 3 age appropriate doses (given at 0, 1-2 mo., and 6-12 mo.) at any age. Adolescents age 11-15 years can be given 2 adult doses (given at 0, and 4-6 mo.).**</td>
<td>All college students.</td>
<td>History of hypersensitivity to any of the components of the vaccine.</td>
</tr>
<tr>
<td><strong>Meningococcal Tetravalent (A,C,Y,W-135)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- <strong>Conjugate (Preferred)</strong></td>
<td>2-55 years (data for revaccination pending).</td>
<td>All adolescents 11-18 years of age, and other populations at increased risk, including freshmen living in dormitories/residence halls, persons with terminal complement deficiencies or asplenia, laboratory personnel with exposure to aerosolized meningococci, and travelers to hyperendemic or endemic areas of the world. Non-freshmen college students may choose to be vaccinated to reduce their risk of meningococcal disease.+</td>
<td>History of hypersensitivity or serious adverse reaction to any of the components in the vaccine. Avoid vaccinating persons who are known to have experienced Guillain-Barre (GBS) syndrome. There is a theoretical risk of increased rates of local or systemic reactions when two diphtheria toxoid-containing vaccines are administered within a short interval (i.e., on different days). Efforts should be made to administer Tdap and tetravalent meningococcal conjugate (MCV4) vaccines simultaneously if both are indicated. If simultaneous vaccination is not feasible, Tdap and MCV4 vaccines (which contain diphtheria toxoid) can be administered in any sequence.</td>
</tr>
<tr>
<td>- <strong>Polysaccharide (Acceptable alternative if conjugate not available)</strong></td>
<td>Over 2 years of age, repeat every 3-5 yrs if increased risk continues.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Other recommendations:

** Combined hepatitis A and B vaccines may be given as a series of 3 doses (given at 0, 1-2 mo., and 6-12 mo.) for 18 years of age and older.

+ Colleges may target all matriculating freshmen if targeting those in dormitories/residence halls is not feasible.
Influenza

- Trivalent inactivated influenza vaccine (TIV)
- Live attenuated influenza vaccine (LAIV; licensed for healthy, nonpregnant persons age 2-49 years).

Health sciences students with patient contact.

Young adults with certain medical conditions: chronic pulmonary disease (including asthma and current history of smoking for college students 19 to 64 years old); chronic cardiovascular disease; diabetes mellitus; chronic liver diseases, including liver disease as a result of alcohol abuse (e.g. cirrhosis); chronic alcoholism, chronic renal failure, or nephrotic syndrome; functional or anatomic asplenia (e.g. sickle cell disease or splenectomy [if elective splenectomy is planned, vaccinate at least 2 weeks before surgery]); immunosuppressive conditions; and cochlear implants and cerebrospinal fluid leaks. Vaccinate as close to HIV diagnosis as possible.

Other indications: certain Alaska Natives and American Indian populations and residents of nursing homes or other long-term care facilities. One-time revaccination after 5 years for persons with chronic renal failure or nephrotic syndrome; functional or anatomic asplenia (e.g. sickle cell disease or splenectomy); or immunosuppressive conditions. For persons aged > 65 years, one-time revaccination if they were vaccinated > 5 years previously and were aged <65 years at the time of primary vaccination.

Influenza - Trivalent inactivated influenza vaccine (TIV)
- Live attenuated influenza vaccine (LAIV; licensed for healthy, nonpregnant persons age 2-49 years).

Pneumococcal Polysaccharide Vaccine-23 valent

Childhood, adolescence, adulthood

Young adults with certain medical conditions: chronic pulmonary disease (including asthma and current history of smoking for college students 19 to 64 years old); chronic cardiovascular disease; diabetes mellitus; chronic liver diseases, including liver disease as a result of alcohol abuse (e.g. cirrhosis); chronic alcoholism, chronic renal failure, or nephrotic syndrome; functional or anatomic asplenia (e.g. sickle cell disease or splenectomy [if elective splenectomy is planned, vaccinate at least 2 weeks before surgery]); immunosuppressive conditions; and cochlear implants and cerebrospinal fluid leaks. Vaccinate as close to HIV diagnosis as possible.

Other indications: certain Alaska Natives and American Indian populations and residents of nursing homes or other long-term care facilities. One-time revaccination after 5 years for persons with chronic renal failure or nephrotic syndrome; functional or anatomic asplenia (e.g. sickle cell disease or splenectomy); or immunosuppressive conditions. For persons aged > 65 years, one-time revaccination if they were vaccinated > 5 years previously and were aged <65 years at the time of primary vaccination.

---

**Other recommendations:**

Immunization requirements and recommendations for international travel may vary, depending on personal medical history and travel destination. Anyone anticipating international travel should contact a health care provider for specific information.
SAMPLE IMMUNIZATION RECORD

This is a SAMPLE immunization record form. If reproduced for use by a college or university health center, please insert your health center’s contact information. This form should not be returned to ACHA.

PART I

Name ___________________________________________________ ________________________________________________

First Name Middle Name

_______________________________________________________________________________________________________

Last Name

Address _____________________________________________________________________________________________________

Street City State Zip

Date of Entry ____/____     Date of Birth  ___/___/___     School ID # __________________________________________________

M       Y M    D     Y

Status   Part-time _____       Full-time _____       Graduate _____       Undergraduate _____        Professional _____

PART II – TO BE COMPLETED AND SIGNED BY YOUR HEALTH CARE PROVIDER.

All information must be in English.

A. M.M.R. (MEASLES, MUMPS, RUBELLA)

(Two doses required at least 28 days apart for students born after 1956 and all health sciences students.)

1. Dose 1 given at age 12 months or later. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . #1 ___/___/___

M    D     Y

2. Dose 2 given at least 28 days after first dose. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . #2 ___/___/___

M    D     Y

B. POLIO

(Primary series, doses at least 28 days apart. Three primary series are acceptable. See ACIP website for details.)

1. OPV alone (oral Sabin three doses):    #1 ___/___/___ #2 ___/___/___ #3 ___/___/___

M    D     Y M    D     Y M    D     Y

2. IPV/OPV sequential:        IPV #1 ___/___/___ IPV #2___/___/___ OPV #3 ___/___/___ OPV #4  ___/___/___

M    D     Y M    D     Y M    D     Y M    D     Y

3. IPV alone (injected Salk four doses):     #1___/___/___ #2 ___/___/___ #3___/___/____ #4___/___/____

M    D     Y M    D     Y M    D     Y M    D     Y

C.   V ARICELLA

(Birth in the U.S. before 1980, a history of chicken pox, a positive varicella antibody, or two doses of vaccine meets the requirement.)

1. History of Disease     Yes _____    No _____      or      Birth in U.S. before 1980     Yes _____    No _____

2. Varicella antibody      ___/___/___ Result:   Reactive _______    Non-reactive ______

M    D     Y

3. Immunization

a.  Dose #1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . #1___/___/___

M     D     Y

b.  Dose #2 given at least 12 weeks after first dose ages 1-12 years #2 ___/___/___ and at least 4 weeks after first dose if age 13 years or older.   M    D     Y

D. TETANUS-DIPHTHERIA-PERTUSSIS

(Primary series with DTaP, DTP, DT, or Td, and booster with Td or Tdap in the last ten years. Health sciences students with patient contact should receive one dose of Tdap at an interval as short as 2 years since last Td as appropriate. Refer to ACIP for details)

1. Primary series of four doses with DTaP, DTP, DT, or Td:

#1  ___/___/___          #2  ___/___/___          #3  ___/___/___          #4  ___/___/___

M    D      Y M     D     Y M    D     Y M    D     Y

2. Booster: Tdap (preferred) to replace a single dose of Td for booster immunization at least 2-5 years since last dose of Td, depending on age of patient. (Administer with MCV4 simultaneously if possible). . . . . . . . . . . . . . . . . . . . . . . . ___/___/___

M    D     Y

3. Booster: Td within the last ten years. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ___/___/___

M    D     Y

(continued)
SAMPLE IMMUNIZATION RECORD (CONT'D.)

E. QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE (HPV)
(Three doses of vaccine for female college students 11-26 years of age at 0, 2, and 6 month intervals.)
Immunization (HPV)
  a. Dose #1 ___/___/___  
  b. Dose #2 ___/___/___  
  c. Dose #3 ___/___/___

F. INFLUENZA
(Trivalent inactivated influenza vaccine or TIV. Live attenuated influenza vaccine or LAIV; licensed for healthy, nonpregnant persons age 5-49 years old. Annual immunization recommended to avoid influenza complications in high-risk patients, to avoid disruption to academic activities, and to limit transmission to high-risk individuals. Health sciences students with patient contact.)
Date ___/___/___ ___/___/___ ___/___/___ ___/___/___ ___/___/___
  TIV___ LAIV___  TIV___ LAIV___  TIV___ LAIV___  TIV___ LAIV___  TIV___ LAIV___

G. HEPATITIS A
1. Immunization (hepatitis A)
  a. Dose #1 ___/___/___
  b. Dose #2 ___/___/___
2. Immunization (Combined hepatitis A and B vaccine)
  a. Dose #1 ___/___/___
  b. Dose #2 ___/___/___
  c. Dose #3 ___/___/___

H. HEPATITIS B
(All college and health sciences students. Three doses of vaccine or two doses of adult vaccine in adolescents 11-15 years of age, or a positive hepatitis B surface antibody meets the requirement.)
1. Immunization (hepatitis B)
  a. Dose #1 ___/___/___
  b. Dose #2 ___/___/___
  c. Dose #3 ___/___/___
  Adult formulation___ Child formulation___  
  Adult formulation___ Child formulation___  
  Adult formulation___ Child formulation___
2. Immunization (Combined hepatitis A and B vaccine)
  a. Dose #1 ___/___/___
  b. Dose #2 ___/___/___
  c. Dose #3 ___/___/___
3. Hepatitis B surface antibody  
  Date ___/___/___
  Result: Reactive_____ Non-reactive_____

I. PNEUMOCOCCAL POLYSACCHARIDE VACCINE
(One dose for members of high-risk groups.)
Date ___/___/___

J. MENINGOCOCCAL TETRAVALENT
(A,C,Y,W-135 / One dose — for college freshmen living in dormitories/residence halls, persons with terminal complement deficiencies or asplenia, laboratory personnel with exposure to aerosolized meningococci, and travelers to hyperendemic or endemic areas of the world. Non-freshmen college students may choose to be vaccinated to reduce their risk of meningococcal disease.)
Tetravalent conjugate (preferred; data for revaccination pending; administer simultaneously with Tdap if possible): Date ___/___/___
Tetravalent polysaccharide (acceptable alternative if conjugate not available; revaccinate every 3-5 years if increased risk continues): Date ___/___/___ ___/___/___

(continued)
SAMPLE IMMUNIZATION RECORD (CONT'D.)

K. TUBERCULOSIS (TB) SCREENING/TESTING

Please answer the following questions:

Have you ever had a positive TB skin test?  Yes _____  No _____

Have you ever had close contact with anyone who was sick with TB?  Yes _____  No _____

Were you born in one of the countries listed below and arrived in the U.S. within the past 5 years?*  Yes _____  No _____
(If yes, please circle _____ the country)

Have you ever traveled** to/in one or more of the countries listed below?  Yes _____  No _____
(If yes, please check ✔ the country/ies)

Have you ever been vaccinated with BCG?  Yes _____  No _____

*future CDC updates may eliminate the 5 year time frame
** The significance of the travel exposure should be discussed with a health care provider and evaluated.

Afghanistan  Congo DR  Kenya  New Caledonia  Sri Lanka
Algeria  Cote d'Ivoire  Kiribati  Nicaragua  Sudan
Angola  Croatia  Korea-DPR  Niger  Suriname
Anguilla  Djibouti  Korea-Republic  Nigeria  Syrian Arab Republic
Argentina  Dominican Republic  Kuwait  Niue  Swaziland
Armenia  Ecuador  Kyrgyzstan  N. Mariana Islands  Tajikistan
Azerbaijan  Egypt  Lao PDR  Pakistan  Tanzania-UR
Bahamas  El Salvador  Latvia  Palau  Thailand
Bahrain  Equatorial Guinea  Lesotho  Panama  Timor-Leste
Bangladesh  Eritrea  Liberia  Papua New Guinea  Togo
Belarus  Estonia  Lithuania  Paraguay  Tonga
Benin  Ethiopia  Macedonia-TFYR  Peru  Tunisa
Bhutan  Fiji  Madagascar  Philippines  Tokelau
Botswana  French Polynesia  Malawi  Poland  Turkey
Bolivia  Gabon  Malaysia  Portugal  Turkmenistan
Bosnia & Herzegovina  Gambia  Maldives  Qatar  Tuvalu
Brazil  Georgia  Mali  Romania  Uganda
Brunei Darussalam  Ghana  Marshall Islands  Russian Federation  Ukraine
Bulgaria  Guatemala  Mauritania  Rwanda  Uruguay
Burkina Faso  Guan  Mauritius  St. Vincent & The Grenadines  Vanuatu
Burundi  Guinea-Bissau  Mexico  Sao Tome & Principe  Venezuela
Cambodia  Guyana  Micronesia  Saudi Arabia  Viet Nam
Cameroon  Haiti  Mongolia  Senegal  Wallis & Futuna Islands
Cape Verde  Honduras  Montenegro  Seychelles  W. Bank & Gaza Strip
Central African Rep.  India  Morocco  Sierra Leone  Yemen
Chad  Indonesia  Mozambique  Singapore  Zambia
China  Iran  Myanmar  Solomon Islands  Zimbabwe
Colombia  Iraq  Namibia  Somalia
Comoros  Japan  Nauru  South Africa
Congo  Kazakhstan  Nepal  Spain

Source: World Health Organization Global Tuberculosis Control, WHO Report 2006, Countries with Tuberculosis incidence rates of > 20 cases per 100,000 population. For future updates, refer to www.who.int/globalatlas/dataQuery/default.asp

If the answer is YES to any of the above questions, __________________________________________________________________________ requires a health care provider complete a tuberculosis risk assessment (to be completed within 6 months prior to the start of classes).

If the answer to all of the above questions is NO, no further testing or further action is required.

1The American College Health Association has published guidelines on “Tuberculosis Screening and Targeted Testing of College and University Students.” To obtain the guidelines, visit www.acha.org.
**SAMPLE IMMUNIZATION RECORD (CONT'D.)**

**TUBERCULOSIS (TB) RISK ASSESSMENT**

Persons with any of the following risk factors are candidates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented:

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recent close contact with someone with infectious TB disease</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Foreign-born from (or travel* to/in) a high-prevalence area (e.g., Africa, Asia, Eastern Europe, or Central or South America)</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Fibrotic changes on a prior chest x-ray suggesting inactive or past TB disease</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Organ transplant recipient</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Human immunodeficiency virus (HIV)/AIDS</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Immunocompromised (equivalent of &gt; 15 mg/d of prednisone for &gt;1 month or TNF-α antagonist)</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>History of illicit drug use</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Resident, employee, or volunteer in a high-risk congregate setting (e.g., correctional facilities, nursing homes, homeless shelters, hospitals, and other health care facilities)</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Medical condition associated with increased risk of progressing to TB disease if infected [e.g., diabetes mellitus, silicosis, head, neck, or lung cancer, hematologic or reticuloendothelial disease such as Hodgkin’s disease or leukemia, end stage renal disease, intestinal bypass or gastrectomy, chronic malabsorption syndrome, low body weight (i.e., 10% or more below ideal for the given population)] | Yes | No |

*The significance of the travel exposure should be discussed with a health care provider and evaluated.

1. **Does the student have signs or symptoms of active tuberculosis disease?**  Yes No

   If No, proceed to 2 or 3. If Yes, proceed with additional evaluation to exclude active tuberculosis disease including tuberculin skin testing, chest x-ray, and sputum evaluation as indicated.

2. **Tuberculin Skin Test (TST)**

   (TST result should be recorded as actual millimeters (mm) of induration, transverse diameter; if no induration, write “0”.
   The TST interpretation should be based on mm of induration as well as risk factors.)*

   **Date Given:** ______/_____/____  **Date Read:** ______/_____/____

   **Result:** ______ mm of induration  **Interpretation:** positive____ negative____

3. **Interferon Gamma Release Assay (IGRA)**

   **Date Obtained:** ______/_____/____  (specify method) QFT-G QFT-GIT other____

   **Result:** negative____ positive____ intermediate____

4. **Chest x-ray: (Required if TST or IGRA is positive)**

   **Date of chest x-ray:** ______/_____/____  **Result:** normal____ abnormal____

   **Interpretation guidelines**

   **>5 mm is positive:**
   - Recent close contacts of an individual with infectious TB
   - Persons with fibrotic changes on a prior chest x-ray consistent with past TB disease
   - Organ transplant recipients
   - Immunocompromised persons: taking > 15 mg/d of prednisone for >1 month; taking a TNF-α antagonist
   - Persons with HIV/AIDS

   **>10 mm is positive:**
   - Persons born in a high prevalence country or who resided in one for a significant* amount of time
   - History of illicit drug use
   - Mycobacteriology laboratory personnel
   - History of resident, worker or volunteer in high-risk congregate setting
   - Persons with the following clinical conditions: silicosis, diabetes mellitus, chronic renal failure, leukemias and lymphomas, head, neck or lung cancer, low body weight (>10% below ideal), gastrectomy or intestinal bypass, chronic malabsorption syndrome

   **>15 mm is positive:**
   - Persons with no known risk factors for TB disease

**HEALTH CARE PROVIDER**

Name ____________________________  Address ____________________________

Signature ____________________________  Phone (_________) ____________________________